ArticleGastroenterology and hepatology from bed to bench2022
Introducing critical common dysregulated proteins in esophageal, gastric, and intestinal cancers.
Article in Gastroenterology and hepatology from bed to bench, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 citations in OpenAlex.
- Evaluation of Synergic Effects of Molybdenum Disulfide Treatment and Near-Infrared Radiation on Human Mesenchymal Stem Cells.Journal of lasers in medical sciences · 2026Article
- Application of network pharmacology in traditional Chinese medicine for the treatment of cardiac diseases.Frontiers in pharmacology · 2025Review
- The Role of CTNNA1 in Malignancies: An Updated Review.Journal of Cancer · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: The current study aimed to determine the common dysregulated proteins between esophageal, gastric, and intestinal cancers. Background: Though there are several documents about the role of AKT1 in promoting of esophageal, gastric, and intestinal cancers, there is not enough evidence about the dominant role of AKT1 relative to the other oncogene genes in the promotion of the three studied cancer types. Methods: One hundred proteins related to each of esophageal, gastric, or intestinal cancer were retrieved from the STRING database and interacted by Cytoscape software v 3.2.7. 2 to create the correlated interactomes. The network was analyzed by the "NetworkAnalyzer" application of Cytoscape to find the centrality parameters of the nodes. Results of network analysis and action map assessment were used to determine the common critical proteins between the three studied cancers. Results: One hundred proteins were extracted for each of the studied cancers. Among 42 common dysregulated proteins, 36 individuals were selected through network analysis and were screened through action map assessment. Eighteen proteins were introduced as the important common proteins. Finally, AKT1 was a candidate for the crucial dysregulated proteins common in the three analyzed diseases. Conclusion: The findings indicate that AKT1, relative to the other oncogene genes, is a suitable candidate to be evaluated in patients as a prediagnostic tool to reduce endoscopy and colonoscopy rates.
Indexed as
Identifiers
35611247PMC9123629W4285742995What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.